Abstract
Neurological manifestations of HCV infection appear to be under-recognized in clinical practice despite the majority of HCV-infected patients experiencing symptoms such as fatigue, depression and cognitive dysfunction. There is also growing evidence for a link between HCV infection and an increased risk of Parkinson's disease. The mechanism underpinning the association between HCV and these neuropsychiatric syndromes still requires further investigation. Here we review the pre-clinical and clinical evidence for a link between HCV and effects on the central nervous system leading to neuropsychiatric syndromes. Lastly, we describe how improvements in neuropsychiatric manifestations of HCV following treatment have been observed, which is subsequently reflected in an overall improvement in health-related quality of life.
MeSH terms
-
Antiviral Agents / therapeutic use*
-
Cognitive Dysfunction / complications
-
Cognitive Dysfunction / drug therapy*
-
Cognitive Dysfunction / epidemiology
-
Cognitive Dysfunction / psychology
-
Depression / complications
-
Depression / drug therapy*
-
Depression / epidemiology
-
Depression / psychology
-
Disease Management
-
Fatigue / complications
-
Fatigue / drug therapy*
-
Fatigue / epidemiology
-
Fatigue / psychology
-
Hepacivirus / drug effects
-
Hepacivirus / pathogenicity
-
Hepacivirus / physiology
-
Hepatitis C, Chronic / complications
-
Hepatitis C, Chronic / drug therapy*
-
Hepatitis C, Chronic / epidemiology
-
Hepatitis C, Chronic / psychology
-
Humans
-
Neuroprotective Agents / therapeutic use
-
Nootropic Agents / therapeutic use
-
Parkinson Disease / complications
-
Parkinson Disease / drug therapy*
-
Parkinson Disease / epidemiology
-
Parkinson Disease / psychology
-
Practice Guidelines as Topic
-
Quality of Life / psychology
-
Risk Factors
Substances
-
Antiviral Agents
-
Neuroprotective Agents
-
Nootropic Agents